HFS
RXRX icon

Hantz Financial Services’s Recursion Pharmaceuticals RXRX Stock Holding History

Hantz Financial Services’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-909
Closed -$4K – 2521
2025
Q3 		$4K Buy
+909
New +$4.77K ﹤0.01% 2073

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Hantz Financial Services's RXRX Position: Q4 2025 in Review

Hantz Financial Services sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 909 shares — an estimated $4K sold.

Hantz Financial Services first reported a position in RXRX in Q3 2025 and held it in 1 quarter. The position peaked at $4K in Q3 2025. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

  • Hantz Financial Services reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Hantz Financial Services sold 909 Recursion Pharmaceuticals shares in Q4 2025, an estimated $4K.
  • Hantz Financial Services first reported a position in Recursion Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Hantz Financial Services's Recursion Pharmaceuticals position peaked at $4K in Q3 2025.
  • 333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Hantz Financial Services's 13F filing for Q4 2025, filed 9 Feb 2026.